Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on January 12, 2016, covering events that occurred on January 6, 2016. The filing addresses corporate governance changes, specifically executive compensation adjustments and board committee appointments.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- CEO (William Annett): New annual base salary of $380,000; 2015 cash bonus of $93,333.
- VP of Research (Karen Chapman): New annual base salary of $230,000; 2015 cash bonus of $55,000.
- VP of Marketing (Kristine Mechem): New annual base salary of $210,000; 2015 cash bonus of $25,000.
- Chairman (Alfred D. Kingsley): 2015 cash bonus of $100,000. Future compensation as non-executive Chairman includes a $50,000 annual cash fee and options to purchase 20,000 shares, vesting quarterly.
Material Changes
Effective January 6, 2016, the Board of Directors increased the annual base salaries for the CEO, VP of Research, and VP of Marketing to align with peer group compensation in the San Francisco Bay Area. Additionally, the Chairman transitioned from an executive role to a non-executive role, with a corresponding change in compensation structure from executive salary to a director fee and equity award.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ from anticipated results due to risk factors detailed in the company's Form 10. No specific financial guidance or operational outlook is provided in this document. The compensation changes are intended to retain talent and align with market standards.
Investor Verification Checklist
- Verify the total cash outflow for the 2015 bonuses and the projected annual increase in salary expenses for 2016.
- Confirm the vesting schedule and valuation of the 20,000 stock options granted to the Chairman.
- Review the company's Form 10 for detailed risk factors referenced in the forward-looking statements.
- Check subsequent filings to confirm the appointment of Andrew Last to the Compensation Committee and his background.